Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
This study is ongoing, but not recruiting participants.
Study NCT00006042 Information provided by National Cancer Institute (NCI)
First Received: July 5, 2000 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Lymphoma
Myelodysplastic Syndromes
Additional conditions recognized in this trial
Lymphoma, Large-Cell, Immunoblastic
Multiple Myeloma
Myelodysplastic-Myeloproliferative Diseases
Myeloproliferative Disorders
Neoplasms
Neoplasms, Plasma Cell
Preleukemia
Syndrome
More general conditions related to this trial
Blood Protein Disorders
Bone Marrow Diseases
Cardiovascular Diseases
Disease
Hematologic Diseases
Hemorrhagic Disorders
Hemostatic Disorders
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Lymphoproliferative Disorders
Neoplasms by Histologic Type
Paraproteinemias
Pathologic Processes
Precancerous Conditions
Vascular Diseases
Interventions listed in this trial
filgrastim
cyclophosphamide
fludarabine phosphate
mycophenolate mofetil
tacrolimus
radiation therapy
Additional drug interventions recognized in this trial
Fludarabine
Fludarabine monophosphate
Mycophenolic Acid
Vidarabine
More general drug interventions related to this trial
Alkylating Agents
Anti-Infective Agents
Antibiotics, Antineoplastic
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antirheumatic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Myeloablative Agonists
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
Sidney Kimmel Comprehensive Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
